ChiCTR1800017526 版本V1.0 版本创建时间2019/09/11 10:57:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1800017526 

最近更新日期:

Date of Last Refreshed on:

2018-08-02 17:39:43 

注册时间:

Date of Registration:

2018-08-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

椎板后路阻滞在腹腔镜下肾切除术后镇痛中的效果观察

Public title:

Effect of retrolaminer block on analgesia after laparoscopic nephrectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

椎板后路阻滞在腹腔镜下肾切除术后镇痛中的效果观察

Scientific title:

Effect of retrolaminer block on analgesia after laparoscopic nephrectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐新鹏 

研究负责人:

刘德行 

Applicant:

Xinpeng Xu 

Study leader:

Dexing Liu 

申请注册联系人电话:

Applicant telephone:

+86 18212034402

研究负责人电话:

Study leader's
telephone:

+86 18685620143

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wzadrsna@126.com

研究负责人电子邮件:

Study leader's E-mail:

pokowenl@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省遵义市汇川区大连路149号

研究负责人通讯地址:

贵州省遵义市汇川区大连路149号

Applicant address:

149 Dalian Road, Huichuan District, Zunyi, Guizhou, China

Study leader's address:

149 Dalian Road, Huichuan District, Zunyi, Guizhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

遵义医学院附属医院

Applicant's institution:

Affiliated Hospital of Zunyi Medical College

研究负责人所在单位:

遵义医学院附属医院

Affiliation of the Leader:

Affiliated Hospital of Zunyi Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018-56

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

遵义医学院附属医院伦理委员会

Name of the ethic committee:

Affiliated Hospital of Zunyi Medical College Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

朱昭琼

Contact Name of the ethic committee:

Zhaoqiong Zhu

伦理委员会联系地址:

贵州省遵义市汇川区大连路149号

Contact Address of the ethic committee:

149 Dalian Road, Huichuan District, Zunyi, Guizhou, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

遵义医学院附属医院

Primary sponsor:

Affiliated Hospital of Zunyi Medical College

研究实施负责(组长)单位地址:

贵州省遵义市汇川区大连路149号

Primary sponsor's address:

149 Dalian Road, Huichuan District, Zunyi, Guizhou, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

Country:

China

Province:

Guizhou

City:

单位(医院):

遵义医学院附属医院

具体地址:

贵州省遵义市汇川区大连路149号

Institution
hospital:

Affiliated Hospital of Zunyi Medical College

Address:

149 Dalian Road, Huichuan District, Zunyi, Guizhou, China

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

Laparoscopic nephrectomy  

Target disease:

腹腔镜下肾切除术

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

不同剂量对照 

Study design:

Dose comparison 

研究目的:

评估椎板后路阻滞在腹腔镜下肾切除术后镇痛的效果  

Objectives of Study:

To evaluate the effect of retrolaminar block on analgesia after laparoscopic nephrectomy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.行腹腔镜下肾切除术
2.年龄在18-70岁之间
3.18≤BMI≤28kg/m2
4.ASA分级Ⅰ-Ⅱ级

Inclusion criteria

1. Patients undergoing laparoscopic nephrectomy;
2. Aged 18-70 years;
3. BMI 18 to 28kg/m2;
4. ASA grade I-II.

排除标准:

1.有严重心、肝、肺功能不全疾患,术后需进ICU继续治疗治疗者
2.凝血功能异常
3.麻醉药物过敏史
4.长期饮酒、慢性疼痛或长期服用精神类药物病史
5.穿刺部位瘢痕、感染、肿瘤
6.恶性高热病史或家族史
7.无法配合随访或依从性差
8.孕妇及哺乳期
9.肾上腺肿瘤
10.严重视觉、听觉障碍,不能阅读文字

Exclusion criteria:

1. Patients with severe heart, liver and pulmonary dysfunction, who need to enter the ICU to continue treatment after surgery
2. Coagulation abnormality
3. History of allergic reactions to anesthetics
4. Long-term drinking, chronic pain, or a history of long-term use of psychotropic drugs
5. Puncture site scars, infection, tumor
6. History or family history of malignant hyperthermia
7. Unable to cooperate with postoperative follow-up or poor compliance
8. Pregnant women and lactation
9. Adrenal tumor patient;
10. With serious visual or hearing impairment.

研究实施时间:

Study execute time:

From 2018-08-01 00:00:00 To 2019-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-08-01 00:00:00 To 2019-12-01 00:00:00

干预措施:

Interventions:

组别:

椎板后路阻滞组

样本量:

60

Group:

Retrolaminer block group

Sample size:

干预措施:

椎板后路阻滞,罗哌卡因,0.4%,30ml

干预措施代码:

Intervention:

Retrolaminer block, Ropivacaine, 0.4%, 30ml

Intervention code:

组别:

局部浸润阻滞组

样本量:

60

Group:

Local infiltration group

Sample size:

干预措施:

局部浸润阻滞,罗哌卡因,0.4%,30ml

干预措施代码:

Intervention:

Local infiltration, Ropivacaine, 0.4%, 30ml

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

遵义 

Country:

China

Province:

Guizhou

City:

Zunyi

单位(医院):

遵义医学院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Zunyi Medical College

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual Analogue Score

Type:

Primary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

病人自控镇痛有效按压次数

指标类型:

主要指标

Outcome:

Number of effective pressing of PCIA

Type:

Primary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

舒芬太尼术后累计消耗量

指标类型:

主要指标

Outcome:

Postoperative cumulative consumption of sufentanil

Type:

Primary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

贝塔-内啡肽

指标类型:

主要指标

Outcome:

β-EP

Type:

Primary indicator

测量时间点:

拔管后30分钟

测量方法:

酶联免疫吸附实验

Measure time point of outcome:

30 minutes after extubation

Measure method:

Enzyme-Linked ImmunoSorbent Assay

指标中文名:

白细胞介素-1贝塔

指标类型:

主要指标

Outcome:

IL-1β

Type:

Primary indicator

测量时间点:

拔管后30分钟

测量方法:

酶联免疫吸附实验

Measure time point of outcome:

30 minutes after extubation

Measure method:

Enzyme-Linked ImmunoSorbent Assay

指标中文名:

血糖

指标类型:

主要指标

Outcome:

Blood glucose

Type:

Primary indicator

测量时间点:

拔管后30分钟

测量方法:

酶联免疫吸附实验

Measure time point of outcome:

30 minutes after extubation

Measure method:

Enzyme-Linked ImmunoSorbent Assay

指标中文名:

前列腺素E2

指标类型:

主要指标

Outcome:

PEG2

Type:

Primary indicator

测量时间点:

拔管后30分钟

测量方法:

酶联免疫吸附实验

Measure time point of outcome:

30 minutes after extubation

Measure method:

Enzyme-Linked ImmunoSorbent Assay

指标中文名:

拔管时间

指标类型:

次要指标

Outcome:

Extubation time

Type:

Secondary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

首次下床活动时间

指标类型:

次要指标

Outcome:

First activity time to out of bed

Type:

Secondary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

术后药物追加情况

指标类型:

次要指标

Outcome:

Postoperative drug additions

Type:

Secondary indicator

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

基础生命体征

指标类型:

次要指标

Outcome:

Basic vital signs

Type:

Secondary indicator

测量时间点:

围术期

测量方法:

监护仪

Measure time point of outcome:

Perioperative period

Measure method:

Monitor

指标中文名:

人口学信息

指标类型:

次要指标

Outcome:

Demographic information

Type:

Secondary indicator

测量时间点:

术前

测量方法:

床旁调查

Measure time point of outcome:

Preoperative

Measure method:

Bedside investigate

指标中文名:

切口感染或裂开

指标类型:

副作用指标

Outcome:

Incision infection or splitting

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

神经损伤

指标类型:

副作用指标

Outcome:

Nerve injury

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

局麻药中毒

指标类型:

副作用指标

Outcome:

local anesthetic intoxication

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

全脊麻

指标类型:

副作用指标

Outcome:

Total spinal anesthesia

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

过敏反应

指标类型:

副作用指标

Outcome:

Allergic reaction

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

指标中文名:

意外猝死

指标类型:

副作用指标

Outcome:

Sudden death

Type:

Adverse events

测量时间点:

术后随访期

测量方法:

床旁调查

Measure time point of outcome:

Postoperative follow-up stage

Measure method:

Bedside investigate

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

静脉

Sample Name:

Blood

Tissue:

Vein

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机随机分配

Randomization Procedure (please state who generates the random number sequence and by what method):

computer random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Not stated

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后,以论文形式共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the paper is published, it will be shared as a paper.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2018-08-02 17:39:43